Vivacy has announced a strategic alliance with Burgeon Biotechnology, an innovative Turkish company based in Ankara, specializing in calcium hydroxyapatite-based biostimulators. This collaboration marks a significant step forward for Vivacy, which will be able to diversify its product range to include advanced skin regeneration solutions.
Burgeon is internationally renowned for its Novuma technology, a new-generation biostimulator designed to improve skin quality by stimulating collagen production. "This product responds directly to growing consumer demand for skin quality and skin rejuvenation. It perfectly complements our existing range of hyaluronic acid-based products. Stylinghyaluronic acid-based products, in which we hold a leading position in Europe", commented Bertrand Frohly, CEO of Vivacy.
By partnering with the Turkish company - present in over 45 countries - the French company gains access to complementary technology, and responds to growing consumer demand for treatments that promote skin quality and regeneration. Novuma is due to be rolled out in Europe over the coming months, with gradual expansion to other regions, consolidating Vivacy's international presence and affirming its commitment to innovation and excellence in the field of aesthetic medicine.
Founded in Paris in 2007, Vivacy is a pioneer in the development, production and distribution of premium hyaluronic acid-based medical devices dedicated to aesthetic and anti-aging medicine. Today, with 200 employees and a diversified geographical presence (80 countries), it is renowned for its Stylage range, produced using its patented technology.
.webp)
.jpg)
.jpg)
